stockrow
Saturday 7 November 2026
Export DRMA’s income statement to Excel — free account
Dermata Therapeutics, Inc.
DRMA Healthcare Biotechnology
- EPS
- +55.4%
- Free cash flow
- +9.99%
Quarter to June 2026, against a year earlier
0.77
0.01
+1.32%
Follow DRMA
Alert me
Dermata Therapeutics, Inc. (DRMA) P/E ratio
Dermata Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)